The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls
Abstract
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with extraordinary tumor-to-background contrast. Currently, gallium 68 (68Ga)–PSMA-11 (or HBED-PSMA) is the most widely used radiotracer for PSMA positron emission tomography (PET)/computed tomography (CT) or PSMA PET/magnetic resonance (MR) imaging. Evolving evidence demonstrates superior sensitivity and specificity of PSMA PET compared to conventional imaging, with frequent identification of subcentimeter prostate cancer lesions. PSMA PET is effective for imaging disease in the prostate, lymph nodes, soft tissue, and bone in a “one-stop–shop” examination. There is emerging evidence for its clinical value in staging of high-risk primary prostate cancer and localization of disease in biochemical recurrence. The high sensitivity provided by PSMA PET, with frequent identification of small-volume disease, is redefining patterns of disease spread compared with those seen at conventional imaging. In metastatic castration-resistant prostate cancer, PSMA PET is frequently used for theranostic selection (eg, lutetium 177–PSMA radionuclide therapy), but its potential use for therapy monitoring is still under debate. However, evidence on its proper use to improve patient-related outcomes, particularly in the setting of early biochemical recurrence and targeted treatment of oligometastatic disease, is still missing. Despite the term prostate specific, PSMA functions as a folate hydrolase and is expressed in a range of normal tissues and in other benign and malignant processes. Knowledge of its physiologic distribution and other causes of uptake is essential to minimize false-positive imaging findings. ©RSNA, 2018
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,236
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
Bubendorf, L., Schöpfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., Gasser, T. C., & Mihatsch, M. J. (2000) · Human Pathology · doi:10.1053/hp.2000.6698 · Cited by 1,895
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
(1997) · PubMed · Cited by 1,541
Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.021 · Cited by 1,007
Self-citationEiber, M., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F.-P., Kübler, H., Haberhorn, U., Eisenhut, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154153 · Cited by 994
Self-citationAfshar-Oromieh, A., Avtzi, E., Giesel, F. L., Holland-Letz, T., Linhart, H. G., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964
Afshar-Oromieh, A., Zechmann, C. M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Holland-Letz, T., Hadaschik, B. A., Giesel, F. L., Debus, J., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2525-5 · Cited by 921
Afshar-Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Hadaschik, B. A., Holland-Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 915
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Eder, M., Schäfer, M., Bauder-Wüst, U., Hull, W.-E., Wängler, C., Mier, W., Haberkorn, U., & Eisenhut, M. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200279b · Cited by 843
Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M., Essler, M., Baum, R. P., Kulkarni, H. R., Schmidt, M., Drzezga, A., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 832
Maurer, T., Gschwend, J. E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., Wester, H.-J., Heck, M., Kübler, H., Beer, A. J., et al. (2016) · Journal of Urology · doi:10.1016/j.juro.2015.12.025 · Cited by 779
Self-citation68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J., Ceci, F., Cho, S., Giesel, F., Haberkorn, U., Hope, T. A., Kopka, K., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3670-z · Cited by 750
Self-citationGiesel, F. L., Hadaschik, B., Cardinale, J., Radtke, J., Vinsensia, M., Lehnert, W., Kesch, C., Tolstov, Y., Singer, S., Grabe, N., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3573-4 · Cited by 592
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
Wright, G. L., Haley, C., Beckett, M. L., & Schellhammer, P. F. (1995) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/1078-1439(95)00002-y · Cited by 591
Morigi, J. J., Stricker, P. D., van Leeuwen, P. J., Tang, R., Ho, B., Nguyen, Q., Hruby, G., Fogarty, G., Jagavkar, R., Kneebone, A., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160382 · Cited by 571
Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer
Eiber, M., Weirich, G., Holzapfel, K., Souvatzoglou, M., Haller, B., Rauscher, I., Beer, A. J., Wester, H.-J., Gschwend, J., Schwaiger, M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.053 · Cited by 568
Self-citationWeineisen, M., Schottelius, M., Simecek, J., Baum, R. P., Yildiz, A., Beykan, S., Kulkarni, H. R., Lassmann, M., Klette, I., Eiber, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158550 · Cited by 532
Self-citationMottet, N., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Schmid, H.-P., Van der Kwast, T., Wiegel, T., Zattoni, F., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.025 · Cited by 493
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 471
Szabo, Z., Mena, E., Rowe, S. P., Plyku, D., Nidal, R., Eisenberger, M. A., Antonarakis, E. S., Fan, H., Dannals, R. F., Chen, Y., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0850-8 · Cited by 443
Budäus, L., Leyh-Bannurah, S.-R., Salomon, G., Michl, U., Heinzer, H., Huland, H., Graefen, M., Steuber, T., & Rosenbaum, C. (2016) · European Urology · doi:10.1016/j.eururo.2015.06.010 · Cited by 429
Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer
Pyka, T., Okamoto, S., Dahlbender, M., Tauber, R., Retz, M., Heck, M., Tamaki, N., Schwaiger, M., Maurer, T., & Eiber, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3435-0 · Cited by 370
Self-citationDietlein, M., Kobe, C., Kuhnert, G., Stockter, S., Fischer, T., Schomäcker, K., Schmidt, M., Dietlein, F., Zlatopolskiy, B. D., Krapf, P., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0866-0 · Cited by 355
Afshar-Oromieh, A., Haberkorn, U., Schlemmer, H. P., Fenchel, M., Eder, M., Eisenhut, M., Hadaschik, B. A., Kopp-Schneider, A., & Röthke, M. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2660-z · Cited by 325
van Leeuwen, P. J., Emmett, L., Ho, B., Delprado, W., Ting, F., Nguyen, Q. A., & Stricker, P. D. (2016) · British Journal of Urology · doi:10.1111/bju.13540 · Cited by 308
Lecouvet, F. E., El Mouedden, J., Collette, L., Coche, E., Danse, E., Jamar, F., Machiels, J.-P., Vande Berg, B., Omoumi, P., & Tombal, B. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.020 · Cited by 303
Herlemann, A., Wenter, V., Kretschmer, A., Thierfelder, K. M., Bartenstein, P., Faber, C., Gildehaus, F.-J., Stief, C. G., Gratzke, C., & Fendler, W. P. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.051 · Cited by 295
Ceci, F., Uprimny, C., Nilica, B., Geraldo, L., Kendler, D., Kroiss, A., Bektic, J., Horninger, W., Lukas, P., Decristoforo, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3078-6 · Cited by 262
van Leeuwen, P. J., Stricker, P., Hruby, G., Kneebone, A., Ting, F., Thompson, B., Nguyen, Q., Ho, B., & Emmett, L. (2016) · BJU International · doi:10.1111/bju.13397 · Cited by 256
Robu, S., Schottelius, M., Eiber, M. J., Maurer, T., Gschwend, J. E., Schwaiger, M., & Wester, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178939 · Cited by 235
Self-citation68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
Rauscher, I., Maurer, T., Fendler, W. P., Sommer, W. H., Schwaiger, M., & Eiber, M. (2016) · Cancer Imaging · doi:10.1186/s40644-016-0072-6 · Cited by 208
Self-citation68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer
Fendler, W. P., Schmidt, D. F., Wenter, V., Thierfelder, K. M., Zach, C., Stief, C., Bartenstein, P., Kirchner, T., Gildehaus, F. J., Gratzke, C., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.172627 · Cited by 202
Krohn, T., Verburg, F. A., Pufe, T., Neuhuber, W., Vogg, A., Heinzel, A., Mottaghy, F. M., & Behrendt, F. F. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2915-3 · Cited by 180
Schuster, D. M., Nieh, P. T., Jani, A. B., Amzat, R., Bowman, F. D., Halkar, R. K., Master, V. A., Nye, J. A., Odewole, O. A., Osunkoya, A. O., et al. (2014) · Journal of Urology · doi:10.1016/j.juro.2013.10.065 · Cited by 172
Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging
Demirci, E., Sahin, O. E., Ocak, M., Akovali, B., Nematyazar, J., & Kabasakal, L. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000566 · Cited by 166
How We Read Oncologic FDG PET/CT
Hofman, M. S., & Hicks, R. J. (2016) · Cancer Imaging · doi:10.1186/s40644-016-0091-3 · Cited by 155
Self-citationDiagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors—Preliminary Analysis
Sasikumar, A., Joy, A., Pillai, M. R. A., Nanabala, R., Muhammed Anees, K., Jayaprakash, P. G., Madhavan, J., & Nair, S. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001451 · Cited by 131
Giesel, F. L., Fiedler, H., Stefanova, M., Sterzing, F., Rius, M., Kopka, K., Moltz, J. H., Afshar‐Oromieh, A., Choyke, P. L., Haberkorn, U., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3106-6 · Cited by 120
68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
Sathekge, M. M., Lengana, T., Modiselle, M., Vorster, M., Zeevart, J., Maes, A., Ebenhan, T., & de Wiele, C. V. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3563-6 · Cited by 120
Jadvar, H., Desai, B., Ji, L., Conti, P. S., Dorff, T. B., Groshen, S. G., Pinski, J., & Quinn, D. I. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114116 · Cited by 117
Pathways of Lymphatic Spread in Male Urogenital Pelvic Malignancies
Paño, B., Sebastià, C., Buñesch, L., Mestres, J., Salvador, R., Macías, N., & Nicolau, C. (2011) · Radiographics · doi:10.1148/rg.311105072 · Cited by 114
Fanti, S., Minozzi, S., Morigi, J. J., Giesel, F., Ceci, F., Uprimny, C., Hofman, M. S., Eiber, M., Schwarzenbock, S., Castellucci, P., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3725-1 · Cited by 113
Self-citation68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma
Sasikumar, A., Joy, A., Nanabala, R., Pillai, M. R. A., Thomas, B., & Vikraman, K. R. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3297-x · Cited by 113
Siva, S., Callahan, J., Pryor, D. I., Martin, J. M., Lawrentschuk, N., & Hofman, M. S. (2017) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12590 · Cited by 103
Self-citationPrasad, V., Steffen, I. G., Diederichs, G., Makowski, M. R., Wust, P., & Brenner, W. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0945-x · Cited by 97
Pfob, C. H., Ziegler, S. I., Graner, F. P., Köhner, M., Schachoff, S., Blechert, B., Wester, H., Scheidhauer, K., Schwaiger, M., Maurer, T., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3424-3 · Cited by 87
Self-citation“Gotta Catch 'em All”, or Do We? Pokemet Approach to Metastatic Prostate Cancer
Murphy, D. G., Sweeney, C. J., & TOMBAL, B. F. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.036 · Cited by 61
Noto, B., Büther, F., Springe, K. A. D., Avramović, N., Heindel, W. L., Schäfers, M. A., Allkemper, T., & Stegger, L. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0261-8 · Cited by 37
Gallium-68 Prostate-Specific Membrane Antigen PET Imaging
Hofman, M. S., & Iravani, A. (2017) · PET Clinics · doi:10.1016/j.cpet.2016.12.004 · Cited by 36
Self-citationSee the unseen: Mesorectal lymph node metastases in prostate cancer
Hijazi, S., Meller, B., Leitsmann, C., Strauß, A., Ritter, C. O., Lotz, J., Meller, J., Trojan, L., & Sahlmann, C. (2016) · The Prostate · doi:10.1002/pros.23168 · Cited by 29
Rieter, W. J., Keane, T. E., Ahlman, M. A., Ellis, C. T., SPICER, K. M., & Gordon, L. L. (2011) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e318219ae29 · Cited by 22
PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer
Maurer, T., Schwamborn, K., Schottelius, M., et al. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.05.020 · Cited by 21
Self-citation
Cited by
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Calais, J., Ceci, F., Eiber, M., Hope, T. A., Hofman, M. S., Rischpler, C., Bach-Gansmo, T., Nanni, C., Savir-Baruch, B., Elashoff, D., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30415-2 · Cited by 476
Self-citationPienta, K. J., Gorin, M. A., Rowe, S. P., Carroll, P. R., Pouliot, F., Probst, S., Saperstein, L., Preston, M. A., Alva, A. S., Patnaik, A., et al. (2021) · Journal of Urology · doi:10.1097/ju.0000000000001698 · Cited by 398
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.01.012 · Cited by 389
Self-citationGiesel, F. L., Knorr, K., Spohn, F., Will, L., Maurer, T., Flechsig, P., Neels, O., Schiller, K., Amaral, H., Weber, W. A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.212233 · Cited by 334
Self-citation
Metadata
- Authors
- Hofman, M. S., Hicks, R. J., Maurer, T., & Eiber, M.
- Venue
- RadioGraphics
- Published
- 2018-01
- Volume
- 38
- Issue
- 1
- Pages
- 200-217
- ISSN
- 0271-5333 (ISSN-L)
- 1527-1323
- OpenAlex
- W2782993602
- Cited by
- 383
- References
- 55
- FWCI
- 22.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.